^
    1d
    Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial
    1d
    A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease (clinicaltrials.gov)
    P2, N=30, Recruiting, Shandong First Medical University | Phase classification: P1/2 --> P2 | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Phase classification • Trial completion date • Trial primary completion date
    7d
    Delayed response with peripheral blood CD8+ T cell expansion during elranatamab therapy in relapsed/refractory multiple myeloma (PubMed, Rinsho Ketsueki)
    Notably, marked peripheral CD8+ T cell expansion was observed at the onset of response, and counts remained elevated during sustained remission. This case suggests that early sFLC reduction is a useful indicator for treatment continuation, and that peripheral CD8+ T-cell dynamics may serve as an on-treatment response biomarker for elranatamab therapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Elrexfio (elranatamab-bcmm)
    11d
    A Study of YKST02 in Participants With Primary IgA Nephropathy (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial
    11d
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=59, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=90 --> 59
    Enrollment closed • Enrollment change
    |
    carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    11d
    Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    13d
    EMN39: A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=1000, Recruiting, European Myeloma Network B.V.
    Trial initiation date
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Lynozyfic (linvoseltamab-gcpt)
    25d
    EPIC: Elranatamab in R/R Multiple Myeloma (clinicaltrials.gov)
    P2, N=32, Recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial primary completion date
    |
    Elrexfio (elranatamab-bcmm) • Abecma (idecabtagene vicleucel)
    25d
    Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) (clinicaltrials.gov)
    P1, N=200, Recruiting, Ichnos Sciences SA | N=80 --> 200
    Enrollment change • First-in-human
    |
    ABBV-2001
    26d
    ELISA in Relapsed/Refractory MM (clinicaltrials.gov)
    P2, N=30, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm) • isatuximab subcutaneous (SAR650984 SC)
    27d
    Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (clinicaltrials.gov)
    P1/2, N=162, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    clonoSEQ
    |
    carfilzomib • pomalidomide • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    28d
    Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=55, Recruiting, AbbVie | Trial completion date: Feb 2027 --> Dec 2027
    Trial completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)